Paratek Pharms Inc patents expiration
1. Nuzyra patents expiration
NUZYRA's oppositions filed in EPO
Can you believe NUZYRA received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7326696 | PARATEK PHARMS INC | Amino-methyl substituted tetracycline compounds |
Sep, 2023
(4 days ago) | |
| US7553828 | PARATEK PHARMS INC | 9-aminomethyl substituted minocycline compounds |
Jun, 2024
(8 months from now) | |
| US8383610 | PARATEK PHARMS INC | Salts and polymorphs of 9-(2,2-dimethylpropyl-aminomethyl) minocycline |
Sep, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9724358 | PARATEK PHARMS INC | Minocycline compounds and methods of use thereof |
Mar, 2029
(5 years from now) | |
| US9265740 | PARATEK PHARMS INC | Minocycline compounds and methods of use thereof |
Mar, 2029
(5 years from now) | |
| US10124014 | PARATEK PHARMS INC | Minocycline compounds and methods of use thereof |
Mar, 2029
(5 years from now) | |
| US9314475 | PARATEK PHARMS INC | Oral and injectable formulations of tetracycline compounds |
Mar, 2031
(7 years from now) | |
| US10111890 | PARATEK PHARMS INC | 9-aminomethyl minocycline compounds and uses thereof |
Aug, 2037
(13 years from now) | |
| US10383884 | PARATEK PHARMS INC | 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP) |
Oct, 2037
(14 years from now) | |
| US10835542 | PARATEK PHARMS INC | 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP) |
Oct, 2037
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Oct 2, 2023 |
| Generating Antibiotic Incentives Now (GAIN) | Oct 2, 2028 |
Drugs and Companies using OMADACYCLINE TOSYLATE ingredient
NCE-1 date: 2027-10-03
Market Authorisation Date: 02 October, 2018
Treatment: Treatment of bacterial skin and skin structure infections; Treatment of bacterial skin and skin structure infection; Treatment of subjects having bacterial skin or skin structure infection; Treatment ...
Dosage: TABLET;ORAL
More Information on Dosage
NUZYRA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic